Australia - English - Department of Health (Therapeutic Goods Administration)

contract manufacturing & packaging services pty ltd - natural fish oil, quantity: 800 mg (equivalent: eicosapentaenoic acid, qty 40 mg; equivalent: docosahexaenoic acid, qty 200 mg); folic acid, quantity: 500 microgram; potassium iodide, quantity: 196.6 microgram (equivalent: iodine, qty 150 microgram) - capsule, soft - excipient ingredients: gelatin; titanium dioxide; iron oxide red; glycerol; hydrogenated vegetable oil; lecithin; cochineal; purified water; soya oil; brilliant blue fcf; d-alpha-tocopherol; iron oxide black; yellow beeswax - maintain/support general health and wellbeing ; aid/assist healthy red blood cell production ; aid/assist/helps protein synthesis in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; maintain/support cognitive function/mental function ; maintain/support brain function ; maintain/support brain/central nervous system development ; helps maintains/support healthy foetal cns/brain development ; maintains/support healthy foetal development ; maintain/support healthy pregnancy ; maintain/support maternal health ; help to prevent neural tube defects such as spina bifida and/or anencephaly ; helps enhance/promote preconception health ; maintain/support preconception health

Australia - English - Department of Health (Therapeutic Goods Administration)

neolife international pty ltd - glycine max, quantity: 225 mg (equivalent: linolenic acid, qty 16.65 mg); triticum aestivum, quantity: 150 mg (equivalent: gluten, qty 0 mg); triticum aestivum, quantity: 10 mg (equivalent: gluten, qty 0.004 mg); oryza sativa, quantity: 300 mg; oryza sativa, quantity: 10 mg; mixed (high-alpha type) tocopherols concentrate, quantity: 2 mg - capsule, soft - excipient ingredients: gelatin; yellow beeswax; titanium dioxide; chlorophyllin-copper complex; purified water; glycerol - antioxidant/reduce free radicals formed in the body ; maintain/support body metabolism/metabolic rate ; maintain/support energy production ; maintain/support eye health ; maintain/support healthy teeth ; anti-inflammatory/relieve inflammation ; maintain/support connective tissue health ; helps enhance/promote bone health ; maintain/support bone health ; helps enhance/promote healthy joint function ; maintain/support joint health ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support muscle health ; maintain/support muscle function ; helps maintain/support cellular uptake of (state vitamin/mineral/nutrient) ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support brain function ; maintain/support nervous system health ; maintain/support nervous system function

India - English - Central Drugs Standard Control Organization

indoco rem. - eicosapentaenoic acid,docosahexaenoic acid - cap - 90mg,60mg(+vit.e,vit.c,zinc sulph.,selenium,vit.b6,mecobalamin,folic acid) - 10

Ireland - English - HPRA (Health Products Regulatory Authority)

epax as - omega-3-acid ethyl esters 90 - capsules, soft - 1000 milligram

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - -  omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). -  usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters. -  laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. -  limitations of use: -  the

United States - English - NLM (National Library of Medicine)

international brand management inc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 1 g in 1 g - each capsule contains 1 gram of omega-3 acid ethyl esters liquid concentrate consisting of at least 900 mg of omega-3 acid ethyl esters.

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 1 g - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp. usage considerations: laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters capsules, usp. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consider

United States - English - NLM (National Library of Medicine)

trygg pharma inc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - omtryg™ (omega-3-acid ethyl esters) capsules, usp, is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia. usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omtryg and should continue this diet during treatment with omtryg. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting omtryg therapy. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems, such as diabetes mellitus and hypothyroidism, that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. limitations of use: the effect of omtryg on the risk for pancreatitis has not

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - lovaza (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (greater than or equal to 500 mg/dl) hypertriglyceridemia. usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving lovaza and should continue this diet during treatment with lovaza. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with lovaza. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consideration of tg-lowering drug therapy. limitations of use: the effect of lovaza on the risk for pancreatitis has not

United States - English - NLM (National Library of Medicine)

meda pharmaceuticals - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 25 mg